Method for stimulating the immune, inflammatory or neuroprotective response
View Patent ↗Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant. Cyclic di-GMP, or a cyclic dinucleotide analogue thereof, also has neuroprotective properties for use as a neuroprotective agent to inhibit, treat, or ameliorate the effects of injuries, diseases,
1. A method for inhibiting or treating an immunological or inflammatory disorder or disease, comprising administering an effective amount of cyclic di-GMP or a cyclic dinucleotide analogue thereof to a patient, thereby stimulating or enhancing the immune or inflammatory response in the patient.
2. The method of claim 1 , wherein the immunological or inflammatory disorder or disease is selected from the group consisting of arthritis, cancer, an autoimmune disorder or disease, a chronic infectious disease, an infectious disease in which the pathogen or toxin produced impairs the immune response, and an immunodeficiency disease or disorder.
3. The method of claim 1 , wherein the immunological or inflammatory disorder or disease is an infectious disease.
4. The method of claim 3 , wherein the infectious disease is caused by a fungi.
5. The method of claim 4 , wherein the fungi is a Cryptococcus spp.
6. The method of claim 5 , wherein the Cryptococcus species is Cryptococcus neoformans.
7. The method of claim 4 , wherein the fungi is Candida albicans.
8. The method of claim 4 , wherein the fungi is Pneumocystis carinii.
9. The method of claim 4 , wherein the fungi is selected from the group consisting of Histoplasma spp., Blastomyces spp. and Coccidioides spp.
10. The method of claim 3 , wherein the infectious disease is caused by a virus.
11. The method of claim 10 , wherein the virus is a respiratory virus which causes an upper respiratory tract viral infection.
12. The method of claim 11 , wherein the virus is an influenza virus.
13. The method of claim 3 , wherein the infectious disease is caused by a bacteria.
14. The method of claim 13 , wherein the bacteria is Klebsiella pneumoniae.
15. The method of claim 13 , wherein the bacteria is Francisella tularensis.
16. The method of claim 13 , wherein the infectious disease is secondary pneumonia following an upper respiratory tract viral infection.
17. The method of claim 16 , wherein the bacteria is selected from the group consisting of Haemophilus influenza, Staphylococcus aureus, Streptococcus pyogenes, Mycoplasma pneumoniae , and Streptococcus pneumoniae.
18. A method for enhancing an immune response to a vaccine, comprising administering an effective amount of a cancer vaccine or antigen to a patient in need thereof in combination with an effective amount of cyclic di-GMP or a cyclic dinucleotide analogue thereof.
19. The method of claim 18 , wherein the immune response is a cellular response.
20. The method of claim 18 , wherein the cancer vaccine is an autologous cancer vaccine.
21. The method of claim 18 , wherein the cancer vaccine is an allogeneic cancer vaccine.
22. A method for treating asthma, comprising administering an effective amount of cyclic di-GMP or a cyclic dinucleotide analogue thereof to a patient in need thereof to inhibit or treat asthma.
23. The method of claim 22 , wherein an effective amount of cyclic di-GMP is administered to the patient in need thereof.
24. The method of claim 22 , wherein an effective amount of a cyclic dinucleotide analogue of cyclic di-GMP is administered to the patient in need thereof.
25. The method of claim 24 , wherein said cyclic dinucleotide analogue is selected from the group consisting of cyclic dinucleotide compounds (I)-(XX)
26. A method for stimulating or enhancing an immune response in a patient, comprising:
activating dendritic cells or T cells with an antigen and with cyclic di-GMP or a cyclic dinucleotide analogue thereof; and
administering the activated dendritic cells or T cells as a cellular vaccine to stimulate or enhance an immune response in the patient.
27. The method of claim 26 , wherein said cyclic dinucleotide analogue is selected from the group consisting of cyclic dinucleotide compounds (I)-(XX)
28. The method of claim 18 , wherein said cyclic dinucleotide analogue is selected from the group consisting of cyclic dinucleotide compounds (I)-(XX)
29. The method of claim 1 , wherein said cyclic dinucleotide analogue is selected from the group consisting of cyclic dinucleotide compounds (I)-(XX)